华熙生物前高管45万字手撕“玻尿酸女王”，“财务造假”内幕曝光

Core Viewpoint - Huaxi Biological is facing serious allegations of financial misconduct, including accusations of financial fraud and inflated revenue figures, as detailed by a former employee who plans to publish a comprehensive exposé [1][2][4]. Group 1: Allegations and Responses - The former employee, known as David, claims to have evidence of financial fraud involving Huaxi Biological's major shareholder, Huaxi Xinyu Investment Co., including concealing shareholdings and fraudulent bond issuance [1][2]. - Huaxi Biological has publicly responded, stating that the allegations are unfounded and that the accuser has a history of misconduct, including embezzlement [2][20]. - The company has previously faced similar allegations during its IPO process in 2019, which were investigated and deemed unsubstantiated by regulatory bodies [22][23]. Group 2: Financial Performance and Irregularities - As of August 7, Huaxi Biological's stock price has plummeted to 52.19 RMB per share, a decline of over 80% from its peak of 299 RMB in July 2021 [3]. - Significant discrepancies in financial data were noted, particularly in 2017, where the half-year revenue was reported at 278 million RMB, vastly exceeding the annual revenue of 3.03 million RMB [9][10][11]. - The company’s financial reports indicated unusual spikes in revenue and expenses, raising concerns about the accuracy of their financial disclosures [4][15]. Group 3: Internal Conflicts and Governance Issues - This incident marks the fourth time Huaxi Biological has been embroiled in disputes with former employees, highlighting ongoing governance challenges and trust issues within the company [29][32]. - Recent reports indicate a significant decline in the company's revenue and net profit, with a 11.6% drop in revenue to 5.371 billion RMB and a 70.6% decrease in net profit to 174 million RMB in 2024 [32]. - The company is also facing public scrutiny due to internal conflicts and allegations of workplace misconduct, which coincide with its declining financial performance [30][32].